Reviving Potential: How Race Oncology’s Breakthrough Could Redefine Cancer Treatment

March 21, 2025 11:37 AM AEDT | By Team Kalkine Media
 Reviving Potential: How Race Oncology’s Breakthrough Could Redefine Cancer Treatment
Image source: shutterstock

Highlights 

  • Race Oncology brings back a shelved cancer drug with modern innovation 
  • New formulation offers 20 years of exclusive patent protection 
  • Potential heart-protective benefits in combination chemotherapy 

Race Oncology (ASX:RAC) is turning heads in the biotech sector with its novel approach to revitalising a once-abandoned cancer drug. The company has re-engineered Bisantrene, a treatment previously approved for acute myeloid leukaemia (AML), addressing the formulation issues that led to its discontinuation and uncovering new therapeutic benefits in the process. 

Originally sidelined due to its poor solubility in blood, Bisantrene presented significant clinical challenges. The drug’s original formulation caused severe side effects, which eventually halted its progression in the market. However, Race Oncology saw an opportunity to bring this promising compound back to life through a modern pharmaceutical lens. 

The company developed a new formulation that overcomes these solubility hurdles, making the drug safer and more effective for patient use. This breakthrough not only addresses the original shortcomings but also qualifies the new version for fresh patent protection—providing Race Oncology with a 20-year exclusivity window to explore its commercial and clinical potential. 

Beyond simply reviving an old drug, further research revealed an unexpected and potentially game-changing benefit. Bisantrene appears to offer cardioprotective effects, particularly when used alongside anthracyclines—one of the most widely used classes of chemotherapy drugs. Anthracyclines are known for their effectiveness in fighting cancer but are also notorious for causing heart damage with prolonged use. 

The dual capability of Bisantrene—to enhance the efficacy of anthracyclines while simultaneously protecting the heart—could mark a major advancement in oncology treatment. This innovation opens doors for safer, more effective chemotherapy regimens, with reduced long-term health complications for patients. 

Race Oncology’s approach highlights the power of scientific reinvention. By revisiting a compound with proven anti-cancer activity and applying modern formulation technologies, the company is unlocking new value in a space that desperately needs fresh solutions. With exclusivity secured and development pathways expanding, the next chapters in Bisantrene’s journey could play a pivotal role in shaping the future of cancer care. 


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.


AU_advertise

Advertise your brand on Kalkine Media

Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.